Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) EBIT (2023 - 2025)

Historic EBIT for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to -$33.0 million.

  • Monte Rosa Therapeutics' EBIT fell 2430.73% to -$33.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.5 million, marking a year-over-year increase of 10659.87%. This contributed to the annual value of -$81.1 million for FY2024, which is 4340.14% up from last year.
  • According to the latest figures from Q3 2025, Monte Rosa Therapeutics' EBIT is -$33.0 million, which was down 2430.73% from -$15.6 million recorded in Q2 2025.
  • Monte Rosa Therapeutics' EBIT's 5-year high stood at $44.0 million during Q1 2025, with a 5-year trough of -$37.2 million in Q2 2023.
  • Over the past 3 years, Monte Rosa Therapeutics' median EBIT value was -$33.0 million (recorded in 2025), while the average stood at -$20.8 million.
  • Examining YoY changes over the last 5 years, Monte Rosa Therapeutics' EBIT showed a top increase of 22600.8% in 2025 and a maximum decrease of 2430.73% in 2025.
  • Monte Rosa Therapeutics' EBIT (Quarter) stood at -$34.9 million in 2023, then skyrocketed by 137.3% to $13.0 million in 2024, then plummeted by 353.58% to -$33.0 million in 2025.
  • Its EBIT was -$33.0 million in Q3 2025, compared to -$15.6 million in Q2 2025 and $44.0 million in Q1 2025.